Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.57 |
| ▸ | TACR1 known ✓ | P25103 | 1/20 | 0.50 |
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.48 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.48 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.52 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | NPY1R | P25929 | 1/20 | 0.47 |
| ▸ | NPY2R | P49146 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8027739 | 1.00 | MMP8 (0.57) | MMP8ELANEHPRT1TP53TACR1 | |
| SCHEMBL6322057 | 0.98 | MMP8 (0.59) | MMP8ELANEHPRT1TP53TACR1 | |
| SCHEMBL4765072 | 0.98 | MMP8 (0.59) | MMP8ELANEHPRT1TP53TACR1 | |
| Hydrochloric Acid SCHEMBL1168459 | 0.87 | MMP8 (0.57) | MMP8ELANEHPRT1TP53TACR1 | |
| Hydrochloric Acid SCHEMBL1168461 | 0.87 | MMP8 (0.57) | MMP8ELANEHPRT1TP53TACR1 | |
| Hydrochloric Acid SCHEMBL7327532 | 0.87 | ATM (0.61) | POLBALDH1A1GAARAB9AATM | |
| Hydrochloric Acid SCHEMBL8724387 | 0.87 | ATM (0.61) | POLBALDH1A1GAARAB9AATM | |
| Hydrochloric Acid SCHEMBL13724226 | 0.86 | MMP8 (0.56) | MMP8ELANEHPRT1TP53TACR1 | |
| SCHEMBL18202478 | 0.86 | POLB (0.51) | MMP8HPRT1TACR1POLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL13724224 | 0.86 | MMP8 (0.56) | MMP8ELANEHPRT1TP53TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080166362-A1 | New effector conjugates, process for their production and their pharmaceutical use | BERGER MARKUS | 2008-07-10 | — | — | US | disclosed |
| US-7335775-B2 | Effector conjugates, process for their production and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-02-26 | — | — | US | disclosed |
| US-20070088060-A1 | New effector conjugates, process for their production and their pharmaceutical use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-04-19 | — | — | US | disclosed |
| US-7129254-B2 | Effector conjugates, process for their production and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-10-31 | — | — | US | disclosed |
| US-6914138-B2 | Urea nucleosides as therapeutic and diagnostic agents | GILEAD SCIENCES, INC. (US) | 2005-07-05 | — | — | US | disclosed |
| EP-1524979-A2 | NEW EFFECTOR CONJUGATES, PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE | Schering AG (DE) | 2005-04-27 | — | — | EP | disclosed |
| US-20050026971-A1 | New effector conjugates, process for their production and their pharmaceutical use | SCHERING AG (DE) | 2005-02-03 | — | — | US | disclosed |
| WO-2004012735-A2 | NEW EFFECTOR CONJUGATES, PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE | SCHERING AG (DE) | 2004-02-12 | — | — | WO | disclosed |
| US-20030069414-A1 | Urea nucleosides as therapeutic and diagnostic agents | GILEAD SCIENCES, INC. | 2003-04-10 | — | — | US | disclosed |
| US-6441161-B1 | REACTING A NUCLEOSIDE WITH A VINYLSTANNANE COMPOUND AND CARBON MONOXIDE | GILEAD SCIENCES, INC. | 2002-08-27 | — | — | US | disclosed |
| US-6143882-A | REACTING A NUCLEOSIDE STARTING MATERIAL CONTAINING A LEAVING GROUP WITH A VINYLSTANNE OF DEFINED FORMULA AND CARBON MONOXIDE IN PRESENCE OF A PALLADIUM CATALYST TO FORM AN ENE-ONE INTERMEDIATE, REACTING WITH AN AMINE, AND ISOLATING | NEXSTAR PHARMACEUTICALS, INC. (US) | 2000-11-07 | — | — | US | disclosed |
| US-6121325-A | Naphthyl compounds promote release of growth hormone | MERCK & CO., INC. (US) | 2000-09-19 | — | — | US | disclosed |
| US-5959100-A | NOVEL COMPOUNDS USEFUL AS DIAGNOSTIC AGENTS AND AS ANTITUMOR, ANTIVIRAL AND/OR ANTIBIOTIC THERAPEUTIC AGENTS | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| WO-1997035868-A9 | UREA NUCLEOSIDES AS THERAPEUTIC AND DIAGNOSTIC AGENTS | — | 1997-12-24 | — | — | WO | disclosed |
| EP-0730578-A4 | INDOLYL GROUP CONTAINING COMPOUNDS AND THE USE THEREOF TO PROMOTE THE RELEASE OF GROWTH HORMONE(S) | MERCK & CO INC (US) | 1997-10-08 | — | — | EP | disclosed |
| WO-1997035868-A1 | UREA NUCLEOSIDES AS THERAPEUTIC AND DIAGNOSTIC AGENTS | NEXSTAR PHARMACEUTICALS, INC. (US) | 1997-10-02 | — | — | WO | disclosed |
| US-5663171-A | FOR USE IN HUMANS OR ANIMALS | MERCK & CO., INC. (US) | 1997-09-02 | — | — | US | disclosed |
| EP-0730578-A1 | INDOLYL GROUP CONTAINING COMPOUNDS AND THE USE THEREOF TO PROMOTE THE RELEASE OF GROWTH HORMONE(S) | MERCK & CO. INC. (US) | 1996-09-11 | — | — | EP | disclosed |
| WO-1995014666-A1 | INDOLYL GROUP CONTAINING COMPOUNDS AND THE USE THEREOF TO PROMOTE THE RELEASE OF GROWTH HORMONE(S) | MERCK & CO., INC. (US) | 1995-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080166362-A1 | New effector conjugates, process for their production and their pharmaceutical use | EPOR, TIE1, TEK | MMP8 111/4885TACR1 2294/4885PPARG 3807/4885 |
| US-20050026971-A1 | New effector conjugates, process for their production and their pharmaceutical use | EPOR, TIE1, TEK | MMP8 111/4885TACR1 2294/4885PPARG 3807/4885 |
| US-20070088060-A1 | New effector conjugates, process for their production and their pharmaceutical use | EPOR, TIE1, TEK | MMP8 111/4885TACR1 2294/4885PPARG 3807/4885 |
| US-20030069414-A1 | Urea nucleosides as therapeutic and diagnostic agents | NUDT1, ADAR, DUT | MMP8 1715/4885TACR1 4744/4885PPARG 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.